BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Xigen Closes Private Investor Financing Round


10/19/2005 5:08:41 PM

January 19, 2004 – Lausanne, Switzerland – Xigen SA, a privately held biopharmaceutical company focusing on research and development of a novel class of cell penetrating therapeutics, announced today the closing of a private investor financing round.

The proceeds from this financing will be used for safety and toxicology testing of Xigen’s lead compounds in the field of neurodegenerative disorders, where the compounds have demonstrated high efficacy in various preclinical disease models.

“Many companies are looking for neuroprotective compounds with new modes of action and with better safety profiles. We are convinced that our JNK inhibitors will be excellent candidates. This financing will help us to further investigate the safety and toxicology of our compounds before moving into clinical trials”, commented Peter Harboe-Schmidt, co-founder and CEO of Xigen.

Following the financing, Thomas Meyer and Alain Nicod have joined the board of Xigen. Both are established entrepreneurs with extensive track records in successfully starting and building companies.

Over 14 years, Thomas Meyer assisted and finally led Disetronic as the CEO, building it into one of the worlds leading suppliers of infusion and injection systems for drug medication. Alain Nicod who is currently managing partner at Venture Incubator brings a wealth of start-up experience from different industry sectors.

In 2003 Xigen was named by CASH, the Swiss business magazine, as one of the 10 most promising Swiss biotechnology start-up companies since 2001. About Xigen (www.xigen.ch)

Xigen S.A. is a Swiss biopharmaceutical company focusing on research and development of novel intracellular peptide therapeutics. The company is a spin-off from the University Hospital of Lausanne (CHUV) and was founded in 2002 in Lausanne, Switzerland. Xigen is developing a novel class of intracellular therapeutic drugs with greatly improved specificity compared to existing drugs. The therapeutics consist of short chained, cell-penetrating peptides that very efficiently block undesired protein-protein interactions. Xigen has first targeted the JNK pathway, which is of major importance in programmed cell death (apoptosis). It has been shown to be of key relevance in neurodegenerative disorders such as stroke, Parkinson’s disease, Alzheimer’s disease and sensorineural hearing loss. Xigen’s neuroprotecting peptide drugs are designed to block the JNK pathway to prevent the abnormal death of cells in such degenerative disorders.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->